Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.

Competing Interests: HSR has received grants or contracts (institutional) from AstraZeneca, Daiichi Sankyo, F Hoffmann-La Roche/Genentech, Gilead Sciences, Lilly, Merck, Novartis, Pfizer, OBI Pharma, Stemline Therapeutics, and Ambryx; and consultancy, advisory support (personal), or honoraria from NAPO, Mylan, Chugai, and Puma. AB has received support (personal) for participation in advisory boards for AstraZeneca/Daiichi, Eisai, Genentech, Gilead Sciences, Lilly, Menarini, Merck, Mersana, Novartis, Pfizer, and Sanofi; and received funding (institutional) and consulting fees from AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead Sciences, Menarini, Merck, Novartis, Pfizer, and Sanofi. ST has received grants or contracts (institutional) from AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Gilead Sciences, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, and Seattle Genetics; consulting fees (personal) from AADi, Artios, Arvinas, AstraZeneca, Bayer, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Hengrui USA, Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Lilly, Menarini Group, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Systimmune, Tango Therapeutics, Umoja Biopharma, Zentalis, and Zymeworks; and received support for attending meetings or travel (personal) from Gilead Sciences, Jazz Pharmaceuticals, Lilly, and Sanofi.